Browsing by Author "Panfil, Amanda R."

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Mouse model recapitulates the phenotypic heterogeneity of human adult T-cell leukemia/lymphoma in bone
    (Elsevier, 2019-12-01) Kohart, Nicole A.; Elshafae, Said M.; Supsahvad, Wachirapan; Alasonyalılar-Demirer, Aylin; Panfil, Amanda R.; Xiang Jingyu; Dirksen, Wessel P.; Veis, Deborah J.; Green, Patrick L.; Weilbaecher, Katherine N.; Rosol, Thomas J.; ALASONYALILAR DEMİRER, AYLİN; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/Patoloji Anabilim Dalı; EKS-2415-2022
    Adult T-cell leukemia/lymphoma has a unique relationship to bone including latency in the marrow, and development of bone invasion, osteolytic tumors and humoral hypercalcemia of malignancy. To study these conditions, we established and characterized a novel mouse model of ATL bone metastasis. Patient-derived ATL cell lines including three that do not express HTLV-1 oncoprotein Tax (ATL-ED, RV-ATL, TL-0m1), an in vitro transformed human T-cell line with high Tax expression (HT-1RV), and an HTLV-1 negative T-cell lymphoma (Jurkat) were injected intratibially into NSG mice, and were capable of proliferating and modifying the bone microenvironment. Radiography, mu CT, histopathology, immunohistochemistry, plasma calcium concentrations, and qRT-PCR for several tumor-bone signaling mRNAs were performed. Luciferase-positive ATL-ED bone tumors allowed for in vivo imaging and visualization of bone tumor growth and metastasis over time. ATL-ED and HT-1RV cells caused mixed osteolytic/osteoblastic bone tumors, TL-Oml cells exhibited minimal bone involvement and aggressive local invasion into the adjacent soft tissues, Jurkat cells proliferated within bone marrow and induced minimal bone cell response, and RV-ATL cells caused marked osteolysis. This mouse model revealed important mechanisms of human ATL bone neoplasms and will be useful to investigate biological interactions, potential therapeutic targets, and new bone-targeted agents for the prevention of ATL metastases to bone.